Autolus Therapeutics (AUTL) Capital Expenditures (2018 - 2025)

Autolus Therapeutics (AUTL) has 8 years of Capital Expenditures data on file, last reported at -$18.8 million in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures fell 104.65% year-over-year to -$18.8 million; the trailing twelve-month figure through Dec 2025 stood at $1.2 million (down 35.19% YoY), and the FY2025 full-year result was $1.2 million, down 35.19% from the prior year.
• Capital Expenditures for Q4 2025 stood at -$18.8 million, down from $4.4 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $16.1 million in Q4 2021 and bottomed at -$18.8 million in Q4 2025.
• The 5-year median for Capital Expenditures is $1.1 million (2023), against an average of $1.7 million.
• The widest annual swing landed in 2024, when Capital Expenditures sank 720.85%; it then jumped 1385.23% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $16.1 million in 2021, then tumbled by 40.34% to $9.6 million in 2022, then plunged by 84.65% to $1.5 million in 2023, then tumbled by 720.85% to -$9.2 million in 2024, then slumped by 104.65% to -$18.8 million in 2025.
• The last three Capital Expenditures figures came in at -$18.8 million (Q4 2025), $4.4 million (Q3 2025), and $7.3 million (Q2 2025), per Business Quant data.

Peer Comparison